US-based clinical stage biopharmaceutical firm has begun dosing in its Phase I single ascending dose clinical study of MYK-491 to treat dilated cardiomyopathy (DCM).

The oral small molecule MYK-491 is currently being developed in an ongoing collaboration between MyoKardia and Sanofi and is an allosteric modulator of myosin, which improves cardiac contractility in a DCM heart.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Designed for hypertrophic cardiomyopathy, MYK-491 acts on the underlying bio-mechanical defects of the heart muscle.

The randomised, placebo-controlled Phase I trial will evaluate the safety, tolerability, preliminary pharmacokinetics and pharmacodynamics of single ascending oral doses of MYK-491 in healthy volunteers.

The study will measure the potential changes in systolic ejection time, along with other established echocardiographic measures of cardiac contractility.

See Also:

"The preclinical studies indicated that MYK-491 may increase the heart’s contractility, with minimal impact on diastole or relaxation."

MyoKardia chief medical officer Marc Semigran said: “There are currently no approved therapies that address the underlying bio-mechanical causes of DCM, which can lead to chronic, progressive, debilitating heart failure that can shorten life.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Preclinical research across many animal models has demonstrated that MYK-491 may increase the heart’s contractility with minimal adverse effects on myocardial diastolic function, which is also abnormal in DCM patients.”

DCM is characterised by thin and over-expanded left ventricle walls, which decreases the contraction, leading to insufficient blood pumping by the heart, shortness of breath, fatigue, swelling in the extremities, or an irregular heartbeat.

The preclinical studies indicated that MYK-491 may increase the heart’s contractility, with minimal impact on diastole or relaxation.

It is expected that the topline results from the Phase I study will be available in the third quarter of this year.